An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
NCT ID: NCT06204302
Last Updated: 2024-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1800 participants
OBSERVATIONAL
2024-01-05
2024-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Prostate cancer is a common cancer in men that starts in the prostate gland, a male reproductive gland found below the bladder. Non-metastatic means that cancer has not yet spread to other parts of the body.
Darolutamide, enzalutamide, and apalutamide are already approved ARIs for nmPC in the United States (US). They work by blocking androgens (male sex hormones including testosterone) from attaching to proteins in cancer cells in the prostate. This helps to slow down the growth of the cancer cells. The participants will receive their treatments as prescribed by their doctors during routine medical care according to the approved product information.
Researchers want to know more about the use of ARIs and how they affect men with nmPC in the real world. Researchers will only include men who have not been treated with any new type of medication that blocks the action of male sex hormones.
The main purpose of this study is to collect and study information from men with nmPC about:
* the length of time they continued treatment with an ARI as prescribed by their doctors.
* the length of time from the start of the treatment with an ARI until the cancer spreads to other parts of the body.
Data will come from the participants' information stored in a database called Komodo Research Dataset (KRD) in the US.
The data collected will be from May 2019 to June 2023.
Researchers will only track data of eligible US men with nmPC and will follow them for a minimum of 6 months or until the end of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
NCT06013475
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
NCT05202301
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
NCT05362149
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
NCT02106507
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
NCT05534646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Darolutamide
Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Darolutamide as initial treatment.
Darolutamide (Nubeqa, BAY1841788)
Retrospective cohort analysis, using Komodo Research Database (KRD)
Enzalutamide
Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Enzalutamide as initial treatment.
Enzalutamide
Retrospective cohort analysis, using Komodo Research Database (KRD)
Apalutamide
Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Apalutamide as initial treatment.
Apalutamide
Retrospective cohort analysis, using Komodo Research Database (KRD)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Darolutamide (Nubeqa, BAY1841788)
Retrospective cohort analysis, using Komodo Research Database (KRD)
Enzalutamide
Retrospective cohort analysis, using Komodo Research Database (KRD)
Apalutamide
Retrospective cohort analysis, using Komodo Research Database (KRD)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with apalutamide, darolutamide or enzalutamide initiated for the first time in the nmPC stage during the patient identification period.
* Age ≥ 18 years at index date
* At least 6 months of continuous eligibility in medical and pharmacy benefits prior to the index date
* At least 6-months of continuous eligibility only in pharmacy benefits after the index date unless patient died before 6 months.
Exclusion Criteria
* Use of an ARI agent or abiraterone acetate prior to the index date
* Other cancer diagnosis (except prostate and skin cancer) during the 6-month baseline period
* Evidence of metastatic disease any time before or 30 days after index date.
* No claim with a diagnosis for hormone sensitive malignancy status (Z19.1) during the study period
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bayer
Whippany, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for access to information about Bayer's transparency standards and Bayer studies.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22704
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.